Literature DB >> 20489144

N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy.

Hetian Lei1, Gisela Velez, Jing Cui, Arif Samad, David Maberley, Joanne Matsubara, Andrius Kazlauskas.   

Abstract

Proliferative vitreoretinopathy (PVR) is a complication that develops in 5% to 10% of patients who undergo surgery to correct a detached retina. The only treatment option for PVR is surgical intervention, which has a limited success rate that diminishes in patients with recurring PVR. Our recent studies revealed that antioxidants prevented intracellular signaling events that were essential for experimental PVR. The purpose of this study was to test whether N-acetyl-cysteine (NAC), an antioxidant used in a variety of clinical settings, was capable of protecting rabbits from PVR. Vitreous-driven activation of PDGFRalpha and cellular responses intrinsic to PVR (contraction of collagen gels and cell proliferation) were blocked by concentrations of NAC that were well below the maximum tolerated dose. Furthermore, intravitreal injection of NAC effectively protected rabbits from developing retinal detachment, which is the sight-robbing phase of PVR. Finally, these observations with an animal model appear relevant to clinical PVR because NAC prevented human PVR vitreous-induced contraction of primary RPE cells derived from a human PVR membrane. Our observations demonstrate that antioxidants significantly inhibited experimental PVR, and suggest that antioxidants have the potential to function as a PVR prophylactic in patients undergoing retinal surgery to repair a detached retina.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20489144      PMCID: PMC2893657          DOI: 10.2353/ajpath.2010.090604

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  31 in total

1.  Angiotensin II induces transactivation of two different populations of the platelet-derived growth factor beta receptor. Key role for the p66 adaptor protein Shc.

Authors:  S Heeneman; J Haendeler; Y Saito; M Ishida; B C Berk
Journal:  J Biol Chem       Date:  2000-05-26       Impact factor: 5.157

2.  Glial cell proliferation in retinal detachment (massive periretinal proliferation).

Authors:  H Laqua; R Machemer
Journal:  Am J Ophthalmol       Date:  1975-10       Impact factor: 5.258

3.  A comparison of different cellular inocula in an experimental model of massive periretinal proliferation.

Authors:  D M Fastenberg; K R Diddie; N Sorgente; S J Ryan
Journal:  Am J Ophthalmol       Date:  1982-05       Impact factor: 5.258

4.  New paradigms in the treatment of wet AMD: the impact of anti-VEGF therapy.

Authors:  G Menon; G Walters
Journal:  Eye (Lond)       Date:  2009-03       Impact factor: 3.775

5.  Induction of proliferative vitreoretinopathy by a unique line of human retinal pigment epithelial cells.

Authors:  Christian A Wong; Michael J Potter; Jing Z Cui; Tom S Chang; Patrick Ma; Alan L Maberley; William H Ross; Valerie A White; Arif Samad; William Jia; Dan Hornan; Joanne A Matsubara
Journal:  Can J Ophthalmol       Date:  2002-06       Impact factor: 1.882

6.  An in vivo gene therapy approach for experimental proliferative vitreoretinopathy using the truncated platelet-derived growth factor alpha receptor.

Authors:  Yasushi Ikuno; Andrius Kazlauskas
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-07       Impact factor: 4.799

7.  Daunomycin in the treatment of experimental proliferative vitreoretinopathy. Effective doses in vitro and in vivo.

Authors:  P Wiedemann; N Sorgente; C Bekhor; R Patterson; T Tran; S J Ryan
Journal:  Invest Ophthalmol Vis Sci       Date:  1985-05       Impact factor: 4.799

8.  Fluorouracil for the treatment of massive periretinal proliferation.

Authors:  M S Blumenkranz; A Ophir; A J Claflin; A Hajek
Journal:  Am J Ophthalmol       Date:  1982-10       Impact factor: 5.258

Review 9.  Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).

Authors:  A Hochhaus
Journal:  Ann Hematol       Date:  2004       Impact factor: 3.673

Review 10.  Mechanisms in proliferative vitreoretinopathy.

Authors:  Ivana K Kim; Jorge G Arroyo
Journal:  Ophthalmol Clin North Am       Date:  2002-03
View more
  32 in total

1.  Pathological signaling via platelet-derived growth factor receptor {alpha} involves chronic activation of Akt and suppression of p53.

Authors:  Hetian Lei; Gisela Velez; Andrius Kazlauskas
Journal:  Mol Cell Biol       Date:  2011-02-28       Impact factor: 4.272

2.  RasGAP Promotes Autophagy and Thereby Suppresses Platelet-Derived Growth Factor Receptor-Mediated Signaling Events, Cellular Responses, and Pathology.

Authors:  Hetian Lei; Cynthia X Qian; Jinghu Lei; Luis J Haddock; Shizuo Mukai; Andrius Kazlauskas
Journal:  Mol Cell Biol       Date:  2015-03-02       Impact factor: 4.272

3.  Phosphoinositide 3-kinase δ inactivation prevents vitreous-induced activation of AKT/MDM2/p53 and migration of retinal pigment epithelial cells.

Authors:  Haote Han; Na Chen; Xionggao Huang; Bing Liu; Jingkui Tian; Hetian Lei
Journal:  J Biol Chem       Date:  2019-08-29       Impact factor: 5.157

4.  Vascular endothelial growth factor A competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses.

Authors:  Steven Pennock; Andrius Kazlauskas
Journal:  Mol Cell Biol       Date:  2012-03-19       Impact factor: 4.272

Review 5.  Proliferative Vitreoretinopathy: A Review.

Authors:  Sana Idrees; Jayanth Sridhar; Ajay E Kuriyan
Journal:  Int Ophthalmol Clin       Date:  2019

Review 6.  [Pharmacological approach to treatment of proliferative vitreoretinopathy].

Authors:  C S Priglinger; S Priglinger
Journal:  Ophthalmologe       Date:  2013-10       Impact factor: 1.059

7.  Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease.

Authors:  Steven Pennock; David Kim; Shizuo Mukai; Matthew Kuhnle; Dal W Chun; Joanne Matsubara; Jing Cui; Patrick Ma; David Maberley; Arif Samad; Robert J Van Geest; Sarit L Oberstein; Reinier O Schlingemann; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2013-04-09       Impact factor: 4.307

8.  A novel function of p53: a gatekeeper of retinal detachment.

Authors:  Hetian Lei; Marc-Andre Rheaume; Jing Cui; Shizuo Mukai; David Maberley; Arif Samad; Joanne Matsubara; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2012-09       Impact factor: 4.307

Review 9.  Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy.

Authors:  Hetian Lei; Marc-Andre Rheaume; Andrius Kazlauskas
Journal:  Exp Eye Res       Date:  2009-11-25       Impact factor: 3.467

10.  A reactive oxygen species-mediated, self-perpetuating loop persistently activates platelet-derived growth factor receptor α.

Authors:  Hetian Lei; Andrius Kazlauskas
Journal:  Mol Cell Biol       Date:  2013-11-04       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.